Global Leading Market Research Publisher QYResearch announces the release of its latest report “Synthetic Aluminum Silicate – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Synthetic Aluminum Silicate market, including market size, share, demand, industry development status, and forecasts for the next few years.
Executive Summary: Solving Formulation Challenges in Pharmaceutical Development
Formulation scientists face persistent challenges: poor powder flowability leads to inconsistent tablet weights; active pharmaceutical ingredients (APIs) tend to cake or agglomerate; suspensions settle or separate; and moisture-sensitive drugs degrade. Synthetic aluminum silicate addresses these pain points as a multifunctional pharmaceutical excipient with excellent adsorptive and suspending properties. It serves as an adsorbent (binding unwanted moisture or oils), disintegrant (promoting rapid tablet breakup), suspending agent (maintaining uniform dispersion in liquids), and stabilizer (preventing API degradation). This functional versatility, combined with recognized safety and compatibility, makes synthetic aluminum silicate a valuable tool for formulators of oral solid and liquid dosage forms.
According to exclusive QYResearch data, the global market for Synthetic Aluminum Silicate was estimated to be worth US$ 17.40 million in 2024 and is forecast to reach a readjusted size of US$ 26.25 million by 2031, achieving a steady CAGR of 6.2% during the forecast period 2025-2031. In 2024, global production reached 2,125 tons, with an average price of approximately US$ 8,200 per ton. This growth reflects increasing demand for functional excipients in complex drug formulations, the expansion of generic pharmaceutical manufacturing, and the trend toward patient-friendly oral dosage forms.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4944331/synthetic-aluminum-silicate
Product Definition: Physicochemical Properties and Functional Mechanisms
Synthetic aluminum silicate is an inorganic compound produced by the reaction of silicate and aluminum salts, typically appearing as a fine white powder with excellent adsorptive and suspending properties.
Physicochemical Properties:
- Appearance: Fine white to off-white powder, odorless and tasteless
- Particle size: Available in 80 mesh (177 µm), 100 mesh (149 µm), and 200 mesh (74 µm) grades
- Surface area: High (typically 100-300 m²/g by BET method), enabling significant adsorptive capacity
- pH (5% slurry): 6.0-8.0 (neutral to mildly alkaline)
- Loss on drying: ≤5% (typical specification)
- Heavy metals: ≤20 ppm (compliant with pharmacopoeia limits)
- Bulk density: 0.4-0.8 g/cm³ (depends on grade and processing)
Functional Mechanisms in Pharmaceutical Formulations:
| Function | Mechanism | Typical Concentration | Applications |
|---|---|---|---|
| Adsorbent | High surface area binds water, oils, and lipophilic API impurities | 0.5-5% | Moisture-sensitive drugs, oil adsorption in dry granulation |
| Disintegrant | Swells upon contact with aqueous media, rupturing tablet matrix | 2-10% | Immediate-release tablets, orally disintegrating tablets (ODTs) |
| Suspending agent | Increases viscosity of liquid medium, prevents particle sedimentation | 1-5% | Oral suspensions, topical lotions |
| Glidant | Improves powder flowability by reducing interparticle friction | 0.25-2% | High-dose tablet formulations, capsule filling |
| Stabilizer | Prevents API aggregation and crystal growth | 1-10% | Amorphous solid dispersions, nanoparticle formulations |
| Anti-caking agent | Absorbs moisture and prevents powder agglomeration | 0.5-2% | Powder blends, dry powder inhalers |
User Case Example – Orally Disintegrating Tablet (ODT) Formulation:
A global generic pharmaceutical company developed a orally disintegrating tablet for an antiemetic API with poor compressibility and bitter taste. Incorporating synthetic aluminum silicate (200 mesh grade, 5% w/w) as a disintegrant and adsorbent achieved:
- Disintegration time: <30 seconds (target <60 seconds)
- Improved API content uniformity (RSD from 5.2% to 2.1%)
- Enhanced mouthfeel (reduced grittiness vs. crospovidone-based ODTs)
- Stability at 40°C/75% RH for 6 months: no significant change in disintegration time or dissolution profile
The formulation was successfully launched in the US and EU in 2025, with estimated annual excipient consumption of 12 tons.
Exclusive Industry Analysis: Mesh Size Selection and Application Suitability
A critical consideration for formulators is the selection of appropriate particle size grade based on application requirements:
80 Mesh Grade (177 µm – approximately 30% of market revenue):
- Coarsest particle size, highest bulk density, lowest surface area (100-150 m²/g)
- Advantages: Excellent flow properties, low dust generation, rapid sedimentation (useful for some suspension applications)
- Limitations: Slower disintegration, potential grittiness in ODTs or topical formulations
- Preferred applications: High-dose tablet formulations (flow improvement), capsule filling, topical creams (exfoliating effect)
- Typical concentration: 0.5-3% for glidant function; 2-5% for suspension
100 Mesh Grade (149 µm – approximately 45% of market revenue, most commonly used):
- Moderate particle size, balanced properties between 80 and 200 mesh
- Advantages: Best general-purpose grade, acceptable flow, moderate disintegration rate, good suspending properties
- Limitations: Not optimized for any specific function but suitable for most applications
- Preferred applications: General tablet formulations (disintegrant), oral suspensions (suspending agent), capsule formulations
- Typical concentration: 3-8% for disintegrant; 1-4% for suspending agent
200 Mesh Grade (74 µm – approximately 25% of market revenue, fastest growing at 8.5% CAGR):
- Finest particle size, lowest bulk density, highest surface area (200-300 m²/g)
- Advantages: Fastest disintegration, smoothest mouthfeel (ODTs), highest adsorptive capacity, best uniformity in low-dose formulations
- Limitations: Poorer flow (requires glidant addition), higher dust generation during handling, potential agglomeration
- Preferred applications: Orally disintegrating tablets (ODTs), low-dose potent APIs (content uniformity), moisture-sensitive drugs (adsorption), amorphous solid dispersions
- Growth driver: Increasing ODT and pediatric-friendly formulations
Technical Challenge – Content Uniformity in Low-Dose Formulations:
Synthetic aluminum silicate’s particle size distribution and density differences versus API particles can cause segregation during blending. Mitigation strategies include:
- Geometric blending (gradual incorporation of API into excipient)
- Use of finer mesh grade (200 mesh) to reduce density/size differential
- Roller compaction (dry granulation) to create uniform granules
- Real-time near-infrared (NIR) monitoring of blend uniformity
Market Segmentation and Key Players
Segment by Mesh Size (Particle Size):
- 80 Mesh (177 µm): 30% market revenue
- 100 Mesh (149 µm): 45% market revenue
- 200 Mesh (74 µm): 25% market revenue (fastest growing)
Segment by Application:
- Tablets: Approximately 40% of market revenue. Includes immediate-release tablets, ODTs, chewable tablets, and effervescent tablets. Disintegrant and binder functions dominate. Growth driven by generic oral solid dosage expansion and ODT preference.
- Capsules: Approximately 25% of market revenue. Includes hard gelatin and HPMC capsules. Glidant and anti-caking functions dominate. Stable segment with moderate growth (4-5% CAGR).
- Oral Suspensions: Approximately 20% of market revenue. Includes antibiotic suspensions, antacid suspensions, and pediatric formulations. Suspending agent and stabilizer functions dominate. Growth driven by pediatric and geriatric patient preference for liquids.
- Topical Formulations: Approximately 15% of market revenue. Includes creams, lotions, gels, and pastes. Suspending agent, thickening agent, and adsorbent functions dominate. Fastest-growing segment (8% CAGR) driven by dermatological product expansion.
Key Players (partial list):
Kyowa Chemical Industry, Hunan Jiudian Hongyang Pharmaceutical, MLA Industries, Guangdong Xinyuan Technology Development, Nanjing Healthnice Pharmaceutical
Market Concentration Note: According to QYResearch data, the top three players (Kyowa Chemical Industry, Hunan Jiudian Hongyang Pharmaceutical, MLA Industries) collectively account for approximately 68% of global revenue. Kyowa Chemical (Japan) leads in high-purity, pharmaceutical-grade synthetic aluminum silicate with extensive pharmacopoeia compliance documentation. Chinese manufacturers (Hunan Jiudian, Guangdong Xinyuan, Nanjing Healthnice) compete on cost for regional markets. MLA Industries (India) serves the growing South Asian generic pharmaceutical market.
Recent News – Capacity Expansion (November 2025):
Kyowa Chemical Industry announced a ¥2.5 billion (US$16.5 million) expansion of its synthetic aluminum silicate manufacturing facility in Okayama, Japan, increasing annual capacity from 1,200 to 2,000 tons. The expansion includes new particle size classification systems for 200 mesh grade production and enhanced quality control laboratories. The company cited growing demand for ODT-optimized grades from global pharmaceutical customers as the primary driver.
Regulatory and Quality Standards
Pharmacopoeia Compliance (Essential for Pharmaceutical Use):
| Pharmacopoeia | Monograph | Key Tests | Typical Acceptance Criteria |
|---|---|---|---|
| USP-NF | Aluminum Silicate (Synthetic) | Identification, loss on drying, pH, heavy metals, arsenic, microbial limits | Heavy metals ≤20 ppm; As ≤2 ppm; TPC ≤1,000 cfu/g |
| Ph. Eur. | Aluminium Silicate (Synthetic) (Ref. No. 01/2022:2459) | Similar to USP with additional aluminum/silicon ratio determination | Al₂O₃: 25-35%; SiO₂: 55-65%; ratio 0.4-0.6 |
| JP | Synthetic Aluminum Silicate | Identification, purity, loss on drying, microbial limits | Loss on drying ≤5%; ignition loss ≤10% |
| ChP | Synthetic Aluminum Silicate | Corresponds to USP/Ph. Eur. requirements | Conforms to Chinese Pharmacopoeia standards |
Critical Quality Attributes:
- Particle size distribution: Critical for disintegration and flow; must be validated for each application
- Surface area: BET method; impacts adsorptive capacity
- pH: Impacts stability of pH-sensitive APIs
- Loss on drying: Moisture content affects stability and flow
- Residual solvents: Per ICH Q3C guidelines
- Elemental impurities: Per ICH Q3D (Class 1, 2, 3 metals)
Recent Regulatory Development (January 2026):
The USP published a revision to the Synthetic Aluminum Silicate monograph (USP-NF 2026, Issue 2), adding a new BET surface area specification (≥100 m²/g) and updated heavy metals testing from USP <231> (obsolete) to USP <233>/<730> (ICP-MS/OES). The revision also includes a new identification test using X-ray diffraction (XRD) to confirm crystalline structure. Compliance required by January 2027.
Technical Considerations for Formulators
Compatibility with APIs:
- Generally compatible with most APIs; inert nature minimizes interaction risk
- Caution required with: Strongly acidic APIs (pH <3) – potential aluminum leaching; chelating agents (citric acid, EDTA) – potential aluminum binding; cationic drugs (some alkaloids) – potential adsorption reducing bioavailability
- Recommendation: Pre-formulation compatibility studies (DSC, FTIR, HPLC) for novel combinations
Processing Considerations:
- Dry blending: High-shear mixing may reduce particle size; gentle blending preferred
- Granulation: Compatible with wet and dry granulation; in wet granulation, swelling occurs during drying (contributes to disintegration)
- Tablet compression: Low to moderate compressibility; typically used in combination with directly compressible excipients (microcrystalline cellulose, lactose, mannitol)
- Suspension preparation: Requires high-shear mixing for uniform dispersion; let stand 30 minutes to eliminate air bubbles before filling
Storage and Handling:
- Stable under normal storage conditions (15-30°C, ≤65% RH)
- Hygroscopic: Absorbs moisture from air; store in tightly closed containers with desiccant
- Incompatible with: Strong acids (reacts to form soluble aluminum salts), strong bases (may degrade structure)
- Shelf life: Typically 3-5 years from date of manufacture
Analyst’s Perspective: Strategic Imperatives for 2025-2031
Three structural shifts will define the synthetic aluminum silicate market over the forecast period:
- Fine particle (200 mesh) demand growth: The increasing popularity of orally disintegrating tablets and low-dose potent APIs drives demand for finer particle grades with higher surface area and faster disintegration. Suppliers investing in classification and milling capabilities for consistent 200 mesh production will capture this growth segment.
- Pharmacopoeia compliance as market entry barrier: USP/Ph. Eur. compliance requires significant analytical investment (ICP-MS for elemental impurities, XRD for identification, BET for surface area). Smaller manufacturers without these capabilities will be limited to non-pharmaceutical applications or regional markets with less stringent requirements.
- Functional excipient substitution in complex formulations: As drug development moves toward poorly soluble APIs (BCS Class II and IV), synthetic aluminum silicate is increasingly evaluated as a stabilizer in amorphous solid dispersions and as an adsorbent for lipid-based formulations. This functional expansion opens new application segments beyond traditional disintegrant/suspending agent roles.
For pharmaceutical formulation scientists, excipient procurement managers, and generic drug developers, the next 72 months will reward those who understand the nuanced differences between mesh grades, maintain rigorous pharmacopoeia compliance documentation, and recognize synthetic aluminum silicate as a versatile functional excipient—not a commodity filler—critical to modern drug delivery system performance.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
